Manage Tickers Link Financial Account

Has my stock been accused of fraud?Join over 160k users who know.

Ticker	Price	Change($)	Change(%)	Shares	Volume	Prev Close	Open	Gain($)	Gain(%)

Ticker	Status	Jurisdiction	Filing Date	CP Start	CP End	CP Loss	Deadline

Ticker	Case Name	Status	CP Start	CP End	Deadline	Settlement Amt

Ticker	Name	Date	Analyst Firm	Up/Down	Target ($)	Rating Change	Rating Current

Connect Biopharma Announces Reduction in Annualized Exacerbations With Rademikibart in Eosinophilic Driven, Type 2 Asthma Oral Presentations And Improvement In Lung Function with Rademikibart In Eosinophilic Driven, Type 2 Asthma In Two Oral Presentations At European Academy Of Allergy And Clinical Immunology 2025 Annual Congress

Author: Benzinga Newsdesk | June 03, 2025 08:06am

Posted In: CNTB